Ivan O. Rosas, ERS 2022: Therapeutic Intervention for Interstitial Lung Disease in Patients with Rheumatoid Arthritis
TRAIL1 (ClinicalTrials.gov Identifier: NCT02808871) was a phase 2 randomised, double blind, placebo-controlled trial investigating pirfenidone in rheumatoid arthritis-associated interstitial lung disease (RA-ILD). We were delighted to speak to Professor Ivan O. Rosas (Baylor College of Medicine, Baylor Medicine McNair Campus, Houston, TX, USA) around the prognosis, choice of therapeutic intervention and the rationale for investigating antifibrotic agents in RA-ILD.
The abstract ‘Randomized, Double Blinded, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease.‘ (Abstract number: RCT2886) was presented at ERS 2022, 4–6 September, 2022.
- Could you give us a brief overview of interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA)? (0:52)
- How does the presence of ILD in RA influence the prognosis and choice of therapeutic intervention? (3:49)
- What is the rationale for investigating antifibrotic agents in RA-ILD? (5:27)
Disclosures: Ivan O. Rosas discloses consulting for Genentech/Roche and receiving grant/ research support from Genentech/Roche.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ERS meeting 2022.
For further information, please view the published study article here and the design article here.
Share this Video
Related Videos In Interstitial Lung Disease
Jean Elwing, CHEST 2022: Inhaled treprostinil for pulmonary hypertension due to interstitial lung disease – the INCREASE OLE study
INCREASE OLE was the open-label extension of the INCREASE study (NCT02630316), which investigated the safety and efficacy of inhaled treprostinil in patients with pulmonary hypertension due to interstitial lung disease. We caught up with Prof. Jean Elwing (UC Health, Cincinnati, OH, USA) to discuss the methodology, inclusion criteria, and safety and tolerability findings from the […]
Junelle Speller – The Pulmonary Fibrosis Foundation Community Registry
The Pulmonary Fibrosis Foundation (PFF) Registry is collecting data from patients with pulmonary fibrosis (PF) or interstitial lung disease (ILD), lung transplant recipients who have had PF or ILD as well as caregivers and family members of patients to help advance medical research. It was a pleasure to talk with PFF Vice President, Junelle Speller […]
Junelle Speller: Pulmonary Fibrosis Foundation – Unmet Needs in Pulmonary Fibrosis and Interstitial Lung Disease
The Pulmonary Fibrosis Foundation (PFF) Registry is collecting data from patients with pulmonary fibrosis (PF) or interstitial lung disease (ILD), lung transplant recipients who have had PF or ILD as well as caregivers and family members of patients to help advance medical research. touchRESPIRATORY were delighted to talk to PFF Vice President, Junelle Speller around […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!